NEW YORK, Aug. 2, 2013 /PRNewswire/ -- Pomerantz Grossman Hufford Dahlstrom & Gross LLP is investigating claims on behalf of investors of TearLab Corporation (NASDAQ: TEAR) ("TearLab" or the "Company") who purchased TearLab common stock between July 24, 2012 and July 23, 2013 (the "Class Period"). Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, ext. 237.
The investigation concerns whether TearLab and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On August 1, 2013 an article published by the Streetsweeper.com claimed that a survey of some of some doctors listed on the Company's own website as providers of its diagnostic test for dry eye disease showed that a large number of doctors have discontinued the use of the Company's eye testing product. On this news announcement, shares of TearLab fell $1.35 per share or 9.19% to close at $12.85 on intraday trading August 1, 2013.The Pomerantz Firm, with offices in New York, Chicago, San Diego and Florida, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com. CONTACT: Robert S. Willoughby Pomerantz Grossman Hufford Dahlstrom & Gross LLP email@example.com SOURCE Pomerantz Grossman Hufford Dahlstrom & Gross LLP